Bionano Genomics, Inc. (NASDAQ:BNGO) Shares Acquired by Swiss National Bank

Swiss National Bank boosted its stake in Bionano Genomics, Inc. (NASDAQ:BNGOGet Rating) by 11.3% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 683,800 shares of the company’s stock after acquiring an additional 69,600 shares during the quarter. Swiss National Bank owned 0.24% of Bionano Genomics worth $1,764,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BNGO. Blackston Financial Advisory Group LLC purchased a new stake in shares of Bionano Genomics during the fourth quarter worth about $30,000. Resources Investment Advisors LLC. purchased a new stake in Bionano Genomics during the 1st quarter worth approximately $33,000. Rafferty Asset Management LLC acquired a new stake in shares of Bionano Genomics in the fourth quarter worth approximately $41,000. Bayesian Capital Management LP purchased a new stake in shares of Bionano Genomics during the fourth quarter worth approximately $55,000. Finally, CPR Investments Inc. raised its stake in Bionano Genomics by 188.2% in the 1st quarter. CPR Investments Inc. now owns 29,687 shares of the company’s stock valued at $77,000 after purchasing an additional 19,387 shares during the last quarter. Hedge funds and other institutional investors own 28.44% of the company’s stock.

Analysts Set New Price Targets

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $12.00 target price on shares of Bionano Genomics in a report on Monday, July 18th.

Bionano Genomics Stock Down 6.1 %

Shares of BNGO opened at $2.31 on Friday. Bionano Genomics, Inc. has a 52-week low of $1.16 and a 52-week high of $6.28. The company has a quick ratio of 7.01, a current ratio of 7.75 and a debt-to-equity ratio of 0.01. The stock has a fifty day simple moving average of $2.13 and a two-hundred day simple moving average of $1.97. The company has a market capitalization of $669.20 million, a PE ratio of -6.41 and a beta of 2.27.

Insider Activity at Bionano Genomics

In other Bionano Genomics news, Director Yvonne Linney sold 20,000 shares of the business’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $3.62, for a total value of $72,400.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by insiders.

About Bionano Genomics

(Get Rating)

Bionano Genomics, Inc provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight.

Featured Stories

Institutional Ownership by Quarter for Bionano Genomics (NASDAQ:BNGO)

Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.